Ascendis Pharma Strikes $70M Deal with Teijin for Japan Rights to Rare Disease Drugs, Securing Up to $175M Plus Royalties for Endocrinology Drugs
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma A/S has signed an exclusive license agreement with Teijin Limited, granting Teijin the rights to develop and commercialize Ascendis's endocrinology rare disease drugs in Japan. The deal is worth $70 million upfront, with the potential for up to $175 million in milestone payments, plus royalties on sales.

November 29, 2023 | 9:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendis Pharma A/S has secured a significant licensing deal with Teijin Limited for its rare disease drugs in Japan, which includes an upfront payment of $70 million and the potential for additional milestone payments and royalties.
The deal with Teijin Limited is likely to have a positive short-term impact on Ascendis Pharma's stock price due to the immediate influx of $70 million and the potential for future revenue through milestone payments and royalties. This agreement demonstrates progress in the company's commercialization efforts and expansion into the Japanese market, which investors may view favorably.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100